Page 25 - Read Online
P. 25

excitatory postsynaptic potentials, which can remove   this effect. Several agonists and antagonists have been
          the Mg  block. Glycine and its analog D-serine can   developed for laboratory research or used as tools in
                 2+
          amplify  the  response  of  NMDARs  to  activate  them   the discovery of new drugs targeting NMDARs such
          together with glutamate. [4]                        as, D-serine, L-alanine as agonists, and amantadine,
                                                              ketamine, methoxetamine as antagonists.
          Location of NMDA receptor
          NMDA receptors are mainly distributed in the CNS,   Discovery of anti-NMDA receptor encephalitis
          and  contribute  to excitatory  synaptic  transmission.   Several cases of neural deficiency accompanied with
          However, NMDARs are also expressed in the peripheral   teratoma were seen from 1997 to 2004. [13]  In 2005,
          nervous system (PNS), for example, in the peripheral   Vitaliani et al. [14]  analyzed four patients diagnosed with
          terminals of primary afferent nerves innervating the   paraneoplastic encephalitis and five patients who were
          colon.  NMDARs in PNS contribute to nociceptive     reported having similar symptoms. They found that all
                [5]
          stimulus, pain in facial muscles, and edema. Regions   the patients were females, and had teratoma. Most of the
          of the brain that prominently express NMDARs include   patients experienced changes in their personalities, loss
          hippocampus, dentate gyri, forebrain cortex, anterior   of short-term memory, seizures, central hypoventilation,
          cingulate cortex, and piriform cortex. Other areas such   and illusions. Abnormal immune systems were found
          as corpus striatum, thalamus, and granule cells in   in all patients. [14]  Two years later, Dalmau et al. [15]  found
          the cerebellum also express high levels of NMDARs.   that serum and cerebrospinal fluid  (CSF) samples
          Early studies had shown that NMDARs were mainly     from these patients showed positive immunochemistry
          located in the postsynaptic membrane, especially in   reaction with the rat hippocampus. Finally, they found
          the postsynaptic density (PSD), for example, in the   an antibody that could bind to NMDAR expressed in
          dendritic spine in excitatory neurons.  However, recent   cultured neurons or human embryonic kidney 293
                                           [6]
          research has indicated a  more diverse distribution   (HEK 293) cell membranes in an unregulated manner.
          of NMDARs not only in PSD, but also in extra-PSD,   The term “anti-NMDAR encephalitis” was coined in
          presynaptic, and extra-synaptic regions.  Typical   that year. In 2008, the antibody was shown to bind to
                                                 [7]
          examples of extra-synaptic NMDARs are in cerebellum   the NR1 subunit of NMDAR, resulting in the loss of its
          astrocytes and retina ganglion. Factors that influence   ion channel function. [16]
          the activation of extra-synaptic NMDARs include the
          location and activity of neurons, the transporter in   The first case of limbic encephalitis with teratoma
          astrocytes, and glutamate spillover in synapses. [8]  was reported in 2009. Since the antibody could not be
                                                              detected in serum or CSF, it could not be ascertained
          Functions of NMDA receptor                          whether this case was an anti-NMDAR encephalitis. [17]
          NMDA receptors are involved in the development of
          the nervous system, including the survival of neurons,   Probable mechanism of anti-NMDA receptor encephalitis
          maturation of dendrites and axons, synaptic plasticity,   synaptic plasticity
          and formation of neural circuits. In addition, long-term   The autoantibody in the patient’s CSF could reduce the
          potentiation effect mediated by NMDARs is one of the   NMDAR clusters in the synapse by binding, cross-linking
          basic mechanisms in learning and memory.  It has been   and internalization. The reduction was reversible, and
                                                [9]
          proven that over-activation of NMDARs is a potential   dependent on the titer of the autoantibody. Integrality
          mechanism for the occurrence of seizures, dementia   of the neurons, synapses, receptors or proteins in the
          and stroke, while the under-activation of NMDARs is   synapse was not harmed by the antibody. The density
          involved in schizophrenia-like symptoms. [10,11]  In addition,   of the NMDAR clusters could recover four days after
          NMDARs are known to mediate central sensitization in the   deletion of the autoantibody. [18]
          pathogenesis of chronic pain after nociceptive stimulus.
                                                         [12]
          Therefore, NMDARs play a very important role in CNS.  Progress after discovery of anti-NMDA receptor encephalitis
                                                              After the discovery of anti-NMDAR encephalitis,
          Factors regulating NMDA receptor activity           the diagnosis of some clinical signs and syndromes
          The activity of NMDARs is regulated by several factors.   such as catatonia, subacute confusion of memory,
          Glycine  can  amplify  the  response  of  NMDARs  to   seizures, abnormal movements and limbic encephalitis
          glutamine through allosteric effect after binding to NR1   had to be changed. Other forms of encephalitis
          subunit. Polyamines can also potentiate the response   mediated by autoantibodies against synaptic receptors
          of NMDARs to glutamine, while zinc ion can block    were found later, such as anti-AMPA receptor,



            18                                                 Neuroimmunol Neuroinflammation | Volume 1 | Issue 1 | June 2014
   20   21   22   23   24   25   26   27   28   29   30